| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 4.2 | 9.6 |
| Profit before tax | -87.6 | -60.0 |
| Net income | -87.7 | -53.6 |
| EPS (diluted, $ a share) | $-0.68 | $-1.97 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -56.2% |
|---|
10-Q filed with the SEC, NASDAQ: GENB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Generate Biomedicines, Inc.: key numbers
- Share price
- $9.84Close, Nov 17
- Market cap
- $1.27B
- Shares outstanding
- 129.1MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Generate Biomedicines, Inc.
All →Generate Biomedicines Financial Results
Generate Biomedicines reported third quarter 2026 financial results, highlighting a cash position of $404.2 million and progress in its Phase 3 asthma studies for GB-0895. The company also noted a significant collaboration with Zealand Pharma in obesity and metabolic diseases with total potential milestones of nearly $1.2 billion.
“Our third quarter results reflect both strong execution across all of our clinical programs and our continued efforts to push the frontiers of programmable biology and therapeutic intelligence. We are making strong progress with GB-0895 in severe asthma, and the data we shared at ERS in COPD further demonstrated the sustained pharmacological activity to support robust modulation of key biomarkers and twice-a-year dosing.”
Mike Nally, chief executive officer of Generate Biomedicines
Generate Biomedicines Director Frances Arnold Sells $185K of Stock
Frances Arnold, Director, sold 11,409 shares of Generate Biomedicines, Inc. at $16.19 a share, worth $185K in total on Oct 29, 2026. Shares held after the trade: 220,063 (-4.9%).
- Value
- $185K
- Shares
- 11,409
- Price
- $16.19
- Role
- Director
- Holding change
- -4.9%
- Trade date
- Oct 29, 2026